Skip to main content

Table 6 Effects of treatment drugs on in-hospital mortality or good clinical outcome (mRS score ≤ 2 at discharge) among patients with subarachnoid hemorrhage—multivariable analysis subgroup (age, treatment procedure, and concomitant medication of cilostazol) results

From: Fasudil hydrochloride and ozagrel sodium combination therapy for patients with aneurysmal subarachnoid hemorrhage: a cross-sectional study using a nationwide inpatient database

  

< 75 years

≥ 75 years

  

Odds ratio

95% CI

p-value

Odds ratio

95% CI

p-value

In-hospital mortality

F group

Reference

  

Reference

  
 

FO group

0.87

0.73–1.04

0.133

1.02

0.81–1.29

0.839

 

O group

2.25

1.53–3.31

< 0.001

1.67

0.97–2.86

0.065

mRS score ≤ 2 at discharge

F group

Reference

  

Reference

  
 

FO group

0.92

0.84–1.00

0.047

0.95

0.81–1.11

0.506

 

O group

1.07

0.82–1.39

0.622

0.63

0.39–1.03

0.064

  

Clipping

Coiling

  

Odds ratio

95% CI

p-value

Odds ratio

95% CI

p-value

In-hospital mortality

F group

Reference

  

Reference

  
 

FO group

1.04

0.86–1.26

0.686

0.83

0.67–1.03

0.084

 

O group

1.11

0.61–2.04

0.731

2.75

1.86–4.06

< 0.001

mRS score ≤ 2 at discharge

F group

Reference

  

Reference

  
 

FO group

0.95

0.86–1.04

0.260

0.92

0.81–1.03

0.160

 

O group

1.08

0.78–1.49

0.652

0.82

0.60–1.11

0.202

  

Concomitant medication of cilostazol

Non-concomitant medication of cilostazol

  

Odds ratio

95% CI

p-value

Odds ratio

95% CI

p-value

In-hospital mortality

F group

Reference

  

Reference

  
 

FO group

1.13

0.90–1.43

0.290

0.85

0.71–1.02

0.075

 

O group

1.85

0.84–4.04

0.124

1.98

1.39–2.81

< 0.001

mRS score ≤ 2 at discharge

F group

Reference

  

Reference

  
 

FO group

0.99

0.89–1.11

0.887

0.84

0.75–0.93

0.001

 

O group

1.00

0.63–1.60

0.996

0.92

0.70–1.20

0.539

  1. F group: fasudil hydrochloride, FO group: combination of fasudil hydrochloride and ozagrel sodium, O group: ozagrel sodium
  2. CI: confidence interval, mRS: modified Rankin Scale, SAH: subarachnoid hemorrhage
  3. F group data were used for reference
  4. Multivariable factors for subgroup analysis by age: sex, treatment procedure for SAH (clipping, coiling), Japan Coma Scale score on admission, mRS score before onset of stroke, days from onset of subarachnoid hemorrhage to admission (within the 3rd day of onset, within the 4th day of onset to the 7th day of onset), starting time of treatment, ambulance use, Charlson Comorbidity Index (0, ≥ 1), presence of comorbidities (hypertension, diabetes mellitus, dyslipidemia, cerebral infarction, cerebral hemorrhage), concomitant medications (cilostazol, statins, edaravone, antihypertensive drug, antiplatelet drug), use of a specific intensive care unit, use of mechanical ventilation, and hospital case volume
  5. Multivariable factors for subgroup analysis by treatment procedure: sex, age, Japan Coma Scale score on admission, mRS score before onset of stroke, days from onset of subarachnoid hemorrhage to admission (within the 3rd day of onset, within the 4th day of onset to the 7th day of onset), starting time of treatment, ambulance use, Charlson Comorbidity Index (0, ≥ 1), presence of comorbidities (hypertension, diabetes mellitus, dyslipidemia, cerebral infarction, cerebral hemorrhage), concomitant medications (cilostazol, statins, edaravone, antihypertensive drug, antiplatelet drug), use of a specific intensive care unit, use of mechanical ventilation and hospital case volume
  6. Multivariable factors for subgroup analysis by concomitant medication of cilostazol: sex, age, treatment procedure for SAH (clipping, coiling), Japan Coma Scale score on admission, mRS score before onset of stroke, days from onset of subarachnoid hemorrhage to admission (within the 3rd day of onset, within the 4th day of onset to the 7th day of onset), starting time of treatment, ambulance use, Charlson Comorbidity Index (0, ≥ 1), presence of comorbidities (hypertension, diabetes mellitus, dyslipidemia, cerebral infarction, cerebral hemorrhage), concomitant medications (statins, edaravone, antihypertensive drug, antiplatelet drug), use of a specific intensive care unit, use of mechanical ventilation and hospital case volume
Back to article page

Journal of Pharmaceutical Health Care and Sciences

ISSN: 2055-0294

Contact us